WC Biosciences Accelerator Mentor
Arthur Klausner is Executive Chairman of Concarlo Therapeutics, Inc. (a preclinical-stage oncology company targeting the protein p27). He was previously CEO of Goldilocks Therapeutics (kidney-targeted therapeutics); CEO of Gem Pharmaceuticals (non-cardiotoxic doxorubicin analog vs. cancer that was acquired by Monopar Therapeutics); and CEO of Jade Therapeutics (ophthalmic applications of a cross-linked hyaluronic acid polymer that was acquired by EyeGate Pharmaceuticals). Prior to his operating roles, Klausner spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. In addition to Concarlo, he currently serves on the Board of Directors of Monopar Therapeutics and Beryl Therapeutics, as well as on investment advisory boards for the New York University (NYU) Innovation Venture Fund, and NYU Langone Health.